A recent poll found that about 15.5 million Americans have used injectable diabetes medicines like Ozempic and Wegovy to lose ...

What’s happening in California, the impact of Ozempic, a look at some franchisee valuations, Greg Flynn’s thoughts on ...

Meanwhile, Hims & Hers tackles the GLP-1 shortage with a new app; Eli Lilly releases data on tirzepatide efficacy; 23andMe faces privacy concerns; and more.

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

A research team in China has held atoms in a state of quantum superposition for 23 minutes, suggesting tantalizing new ...

New research shows that weight loss medications can stop the progression of prediabetes. Experts don’t all agree on such a ...

Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...

Hims & Hers Health launched a GLP-1 Supply Tracker to spotlight challenges in accessing obesity medications, addressing ...

Ozempic and Wegovy? What even IS a telehealth provider ... in adults with Type 2 diabetes. Compounded semaglutide: Medication ...

Diabetes and weight-loss drug tirzepatide (Mounjaro, Zepbound) was listed as a contributing factor in the death of a 58-year-old nurse from Scotland who died of multiple organ failure, septic shock, ...

GLP-1s seem to be everywhere. The appetite suppressant drugs, with brand names like Ozempic and Wegovy, have grown in ...